Home Tags APEIRON Biologics AG

APEIRON Biologics AG

Ligand Pharmaceuticals Incorporated has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively.

Ligand to Acquire APEIRON Biologics AG for $100 Million

Team SR -
© Copyright startuprise 2024 All Rights Reserved.
Exit mobile version